Satellos Bioscience Inc. MSLE
Set alert
6.75 USD +0.05 +0.75%
As of Nov 2, 9:30 AM ET
6.75 Day range 6.75
5.30 52-week range 13.40
- YTD
- +14.80%
- 1 year
- +3.85%
- Open
- 6.75
- Prev close
- 6.70
- Mkt cap
- 143.21M
- Vol
- 199
- Avg vol
- 42.03K
- EPS
- -1.95
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.75
- High
- 6.75
Financials — quick view
MSLE Revenue — quarterly 0
MSLE Net income — quarterly -11.72M
MSLE EPS — quarterly -0.56
News
- Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24
- Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform
- Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age
- Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Wall Street Brokerages
- FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy
- HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target
- Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate
- HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $18
- Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
- Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Your note
Sign in to keep a note on MSLE — it syncs with the Stock Master app.